These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 32499108

  • 1. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis.
    Laszlo D, Marcacci GP, Martino M, Radice D, Rabascio C, Lucchetti B, Magarò A, Caime A, Menna S, Lionetti MT, Bertolini F.
    Transfus Apher Sci; 2020 Oct; 59(5):102819. PubMed ID: 32499108
    [Abstract] [Full Text] [Related]

  • 2. A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents.
    Mina R, Petrucci MT, Bonello F, Bongarzoni V, Saccardi R, Bertuglia G, Mengarelli A, Spadaro A, Lisi C, Curci P, Lemoli RM, Ballanti S, Floris R, Cupelli L, Tosi P, Olivieri A, Rota-Scalabrini D, Cangialosi C, Nozzoli C, Anaclerico B, Fazio F, Bruno B, Mancuso K, Corradini P, Milone G, Boccadoro M.
    Haematologica; 2024 May 01; 109(5):1525-1534. PubMed ID: 37981892
    [Abstract] [Full Text] [Related]

  • 3. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies.
    Awan F, Kochuparambil ST, Falconer DE, Cumpston A, Leadmon S, Watkins K, Deremer D, Jillella A, Craig M, Hamadani M.
    Bone Marrow Transplant; 2013 Oct 01; 48(10):1279-84. PubMed ID: 23584435
    [Abstract] [Full Text] [Related]

  • 4. Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF+/-plerixafor vs cyclophosphamide/GCSF+/-plerixafor.
    Yang C, Dehghani M, Hopman W, Bhella S.
    J Clin Apher; 2022 Aug 01; 37(4):348-353. PubMed ID: 35218068
    [Abstract] [Full Text] [Related]

  • 5. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
    Chaudhary L, Awan F, Cumpston A, Leadmon S, Watkins K, Tse W, Craig M, Hamadani M.
    J Clin Apher; 2013 Oct 01; 28(5):359-67. PubMed ID: 23765597
    [Abstract] [Full Text] [Related]

  • 6. Optimizing Autologous Stem Cell Transplantation in Multiple Myeloma: The Impact of Intensive Chemomobilization.
    Portuguese AJ, Yeh AC, Banerjee R, Holmberg L, Wuliji N, Green DJ, Mielcarek M, Gopal AK, Gooley T, Stevenson P, Cowan AJ.
    Transplant Cell Ther; 2024 Aug 01; 30(8):774.e1-774.e12. PubMed ID: 38768908
    [Abstract] [Full Text] [Related]

  • 7. Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era.
    Johnsrud A, Ladha A, Muffly L, Shiraz P, Goldstein G, Osgood V, Shizuru JA, Johnston L, Arai S, Weng WK, Lowsky R, Rezvani AR, Meyer EH, Frank MJ, Negrin RS, Miklos DB, Sidana S.
    Transplant Cell Ther; 2021 Jul 01; 27(7):590.e1-590.e8. PubMed ID: 33915323
    [Abstract] [Full Text] [Related]

  • 8. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP, DiPersio JF, Maziarz RT, Stadtmauer EA, Micallef IN, Stiff PJ, Hsu FJ, Bridger G, Bolwell BJ.
    Biol Blood Marrow Transplant; 2012 Oct 01; 18(10):1564-72. PubMed ID: 22683613
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis.
    Lazzaro C, Castagna L, Lanza F, Laszlo D, Milone G, Pierelli L, Saccardi R.
    Bone Marrow Transplant; 2021 Aug 01; 56(8):1876-1887. PubMed ID: 33753907
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.
    Milone G, Martino M, Spadaro A, Leotta S, Di Marco A, Scalzulli P, Cupri A, Di Martina V, Schinocca E, Spina E, Tripepi G.
    Br J Haematol; 2014 Jan 01; 164(1):113-23. PubMed ID: 24138497
    [Abstract] [Full Text] [Related]

  • 16. Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma.
    Avigan ZM, Arinsburg S, Pan D, Mark T, Fausel C, Bubalo J, Milkovich G, Moshier E, Fu W, Chari A, Richter J.
    Bone Marrow Transplant; 2024 Oct 01; 59(10):1440-1448. PubMed ID: 39085373
    [Abstract] [Full Text] [Related]

  • 17. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.
    Shaughnessy P, Islas-Ohlmayer M, Murphy J, Hougham M, MacPherson J, Winkler K, Silva M, Steinberg M, Matous J, Selvey S, Maris M, McSweeney PA.
    Biol Blood Marrow Transplant; 2011 May 01; 17(5):729-36. PubMed ID: 20813198
    [Abstract] [Full Text] [Related]

  • 18. Plerixafor combined with G-CSF for stem cell mobilization in children qualified for autologous transplantation- single center experience.
    Malinowska I, Romiszewski M, Smalisz K, Stelmaszczyk-Emmel A, Nasilowska-Adamska B, Krol M, Urbanowska E, Brozyna A, Baginska-Dembowska B.
    Transfus Apher Sci; 2021 Jun 01; 60(3):103077. PubMed ID: 33583716
    [Abstract] [Full Text] [Related]

  • 19. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
    Chhabra S, Callander N, Watts NL, Costa LJ, Thapa B, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Anderson LD, Bal S, Dhakal B, Nathwani N, Shah N, Medvedova E, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Schmidt T, Orlowski RZ, Shain KH, Cowan AJ, Dholaria B, Cornell RF, Jerkins JH, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG, Voorhees PM.
    Transplant Cell Ther; 2023 Mar 01; 29(3):174.e1-174.e10. PubMed ID: 36494017
    [Abstract] [Full Text] [Related]

  • 20. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.
    Hartmann T, Hübel K, Monsef I, Engert A, Skoetz N.
    Cochrane Database Syst Rev; 2015 Oct 20; 2015(10):CD010615. PubMed ID: 26484982
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.